Center-Authored Papers

Filters: Author is Wang, Eunice S  [Clear All Filters]
Journal Article
Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE et al..  2015.  Acute Lymphoblastic Leukemia, Version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(10):1240-79. Abstract
O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE et al..  2013.  Acute myeloid leukemia, version 2.2013.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(9):1047-55. Abstract
O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE et al..  2017.  Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(7):926-957. Abstract
O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G et al..  2011.  Acute myeloid leukemia.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(3):280-317.
O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S et al..  2012.  Acute myeloid leukemia.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(8):984-1021. Abstract
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB et al..  2016.  Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(12):1572-1611. Abstract
Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW et al..  2017.  NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(9):1091-1102. Abstract
Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.  2012.  A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.. Journal of hematology & oncology. 5:71. Abstract